{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T01:27:05Z","timestamp":1793842025010,"version":"4.6.1"},"reference-count":163,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:00:00Z","timestamp":1793836800000},"content-version":"vor","delay-in-days":369,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001793","name":"Queensland University of Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001793","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ymthe.2025.07.037","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T18:57:37Z","timestamp":1753729057000},"page":"5355-5372","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Rewriting androgen-targeted therapy resistance with non-coding RNAs in prostate cancer treatment"],"prefix":"10.1016","volume":"33","author":[{"given":"Chamikara","family":"Liyanage","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Clements","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4646-6247","authenticated-orcid":false,"given":"Jyotsna","family":"Batra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2025.07.037_bib1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0022-5347(05)64820-3","article-title":"Studies on prostatic cancer - I The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate","volume":"168","author":"Huggins","year":"2002","journal-title":"J. Urol."},{"key":"10.1016\/j.ymthe.2025.07.037_bib2","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12967-024-04878-5","article-title":"New advances of the androgen receptor in prostate cancer: report from the 1st International Androgen Receptor Symposium","volume":"22","author":"Mehralivand","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.ymthe.2025.07.037_bib3","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s13046-024-03125-5","article-title":"Emerging frontiers in androgen receptor research for prostate Cancer: insights from the 2nd international androgen receptor Symposium","volume":"43","author":"Israel","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2025.07.037_bib4","first-page":"87","article-title":"Evolution of Androgen Deprivation Therapy (ADT) and Its New Emerging Modalities in Prostate Cancer: An Update for Practicing Urologists, Clinicians and Medical Providers","volume":"14","author":"Choi","year":"2022","journal-title":"Res. Rep. Urol."},{"key":"10.1016\/j.ymthe.2025.07.037_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15205047","article-title":"Castration-Resistant Prostate Cancer: From Uncovered Resistance Mechanisms to Current Treatments","volume":"15","author":"Le","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ymthe.2025.07.037_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103736","article-title":"Androgen receptor pathway inhibitors and drug-drug interactions in prostate cancer","volume":"9","author":"Bolek","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.ymthe.2025.07.037_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2023.100962","article-title":"Current therapy and drug resistance in metastatic castration-resistant prostate cancer","volume":"68","author":"Cai","year":"2023","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.ymthe.2025.07.037_bib8","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1007\/s11864-023-01121-z","article-title":"Genomic and Phenotypic Biomarkers for Precision Medicine Guidance in Advanced Prostate Cancer","volume":"24","author":"Davoudi","year":"2023","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.ymthe.2025.07.037_bib9","article-title":"Molecular Mechanisms of Noncoding RNA in the Occurrence of Castration-Resistant Prostate Cancer","volume":"24","author":"Lin","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2025.07.037_bib10","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1186\/s12967-024-05554-4","article-title":"A systematic review of non-coding RNA therapeutics in early clinical trials: a new perspective against cancer","volume":"22","author":"Grillone","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.ymthe.2025.07.037_bib11","doi-asserted-by":"crossref","first-page":"291","DOI":"10.31128\/AJGP-11-23-7028","article-title":"Evolution of hormonal therapy for prostate cancer","volume":"53","author":"Homewood","year":"2024","journal-title":"Aust. J. Gen. Pract."},{"key":"10.1016\/j.ymthe.2025.07.037_bib12","first-page":"157","article-title":"Cyproterone acetate in the therapy of prostate carcinoma","volume":"77","author":"Torri","year":"2005","journal-title":"Arch. Ital. Urol. Androl."},{"key":"10.1016\/j.ymthe.2025.07.037_bib13","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/bju.15364","article-title":"Real-world use of first-generation antiandrogens: impact on patient outcomes and subsequent therapies in metastatic castration-resistant prostate cancer","volume":"128","author":"Kelly","year":"2021","journal-title":"BJU Int."},{"key":"10.1016\/j.ymthe.2025.07.037_bib14","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1097\/01.ju.0000140159.94703.80","article-title":"Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years","volume":"172","author":"Wirth","year":"2004","journal-title":"J. Urol."},{"key":"10.1016\/j.ymthe.2025.07.037_bib15","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1158\/1078-0432.CCR-18-1589","article-title":"Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate Cancer","volume":"25","author":"Ferrari","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2025.07.037_bib16","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s11255-015-0919-y","article-title":"Bicalutamide 150 mg as secondary hormonal therapy for castration-resistant prostate cancer","volume":"47","author":"Qian","year":"2015","journal-title":"Int. Urol. Nephrol."},{"key":"10.1016\/j.ymthe.2025.07.037_bib17","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/oncolo\/oyab045","article-title":"Rational Second-Generation Antiandrogen Use in Prostate Cancer","volume":"27","author":"Orme","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.ymthe.2025.07.037_bib18","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1470-2045(15)00518-5","article-title":"Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study","volume":"17","author":"Shore","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ymthe.2025.07.037_bib19","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1200\/JCO.2015.64.9285","article-title":"Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial","volume":"34","author":"Penson","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2025.07.037_bib20","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1200\/JCO.2013.50.1684","article-title":"Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer","volume":"31","author":"Rathkopf","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2025.07.037_bib21","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.eururo.2016.04.023","article-title":"Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort","volume":"70","author":"Smith","year":"2016","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ymthe.2025.07.037_bib22","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S1470-2045(21)00402-2","article-title":"Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study","volume":"22","author":"Saad","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ymthe.2025.07.037_bib23","doi-asserted-by":"crossref","DOI":"10.1038\/srep12007","article-title":"Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies","volume":"5","author":"Moilanen","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2025.07.037_bib24","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.07.037_bib25","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1001\/jamaoncol.2024.0591","article-title":"Metastatic Hormone-Sensitive Prostate Cancer and Combination Treatment Outcomes: A Review","volume":"10","author":"Hussain","year":"2024","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ymthe.2025.07.037_bib26","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12916-022-02263-x","article-title":"Activity and safety of SHR3680, a novel antiandrogen, in patients with metastatic castration-resistant prostate cancer: a phase I\/II trial","volume":"20","author":"Qin","year":"2022","journal-title":"BMC Med."},{"key":"10.1016\/j.ymthe.2025.07.037_bib27","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/S1470-2045(22)00507-1","article-title":"Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial","volume":"23","author":"Gu","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ymthe.2025.07.037_bib28","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/postmj\/qgae063","article-title":"Treatment of metastatic hormone-sensitive prostate cancer: from doublet therapy to triplet therapy","volume":"100","author":"Ye","year":"2024","journal-title":"Postgrad. Med. J."},{"key":"10.1016\/j.ymthe.2025.07.037_bib29","article-title":"Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: An Updated Network Meta-analysis Including ARANOTE Data","author":"Hoeh","year":"2024","journal-title":"Eur. Urol. Focus"},{"key":"10.1016\/j.ymthe.2025.07.037_bib30","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(23)00063-3","article-title":"Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial","volume":"24","author":"Sweeney","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ymthe.2025.07.037_bib31","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/iju.15424","article-title":"Exploring androgen receptor signaling pathway in prostate cancer: A path to new discoveries","volume":"31","author":"Obinata","year":"2024","journal-title":"Int. J. Urol."},{"key":"10.1016\/j.ymthe.2025.07.037_bib32","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1021\/acsptsci.3c00299","article-title":"Updates on Overcoming Bicalutamide Resistance: A Glimpse into Resistance to a Novel Antiandrogen","volume":"7","author":"Izady","year":"2024","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.ymthe.2025.07.037_bib33","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/bph.15300","article-title":"Mechanisms of enzalutamide resistance in castration-resistant prostate cancer and therapeutic strategies to overcome it","volume":"178","author":"Wang","year":"2021","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ymthe.2025.07.037_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13040715","article-title":"SWATH-MS Based Proteomic Profiling of Prostate Cancer Cells Reveals Adaptive Molecular Mechanisms in Response to Anti-Androgen Therapy","volume":"13","author":"Liyanage","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ymthe.2025.07.037_bib35","first-page":"456","article-title":"Metabolic alterations drive enzalutamide resistance","volume":"20","author":"Masone","year":"2023","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.ymthe.2025.07.037_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16071303","article-title":"RNA m6a Methylation Regulator Expression in Castration-Resistant Prostate Cancer Progression and Its Genetic Associations","volume":"16","author":"Liyanage","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ymthe.2025.07.037_bib37","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.trecan.2024.01.004","article-title":"Epigenetic underpinnings of tumor-immune dynamics in prostate cancer immune suppression","volume":"10","author":"Angappulige","year":"2024","journal-title":"Trends Cancer"},{"key":"10.1016\/j.ymthe.2025.07.037_bib38","doi-asserted-by":"crossref","first-page":"6349","DOI":"10.1007\/s00210-024-03736-x","article-title":"Natural products and long non-coding RNAs in prostate cancer: insights into etiology and treatment resistance","volume":"398","author":"Elimam","year":"2025","journal-title":"Naunyn. Schmiedebergs. Arch. Pharmacol."},{"key":"10.1016\/j.ymthe.2025.07.037_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1123101","article-title":"Importance of long non-coding RNAs in the pathogenesis, diagnosis, and treatment of prostate cancer","volume":"13","author":"Taheri","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ymthe.2025.07.037_bib40","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1186\/s12894-024-01634-1","article-title":"MicroRNA in prostate cancer: from biogenesis to applicative potential","volume":"24","author":"Luo","year":"2024","journal-title":"BMC Urol."},{"key":"10.1016\/j.ymthe.2025.07.037_bib41","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1373\/clinchem.2018.299651","article-title":"Emergence of MicroRNAs as Key Players in Cancer Cell Metabolism","volume":"65","author":"Subramaniam","year":"2019","journal-title":"Clin. Chem."},{"key":"10.1016\/j.ymthe.2025.07.037_bib42","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1373\/clinchem.2015.242800","article-title":"MicroRNA Theranostics in Prostate Cancer Precision Medicine","volume":"62","author":"Matin","year":"2016","journal-title":"Clin. Chem."},{"key":"10.1016\/j.ymthe.2025.07.037_bib43","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15123140","article-title":"Deregulated microRNAs Involved in Prostate Cancer Aggressiveness and Treatment Resistance Mechanisms","volume":"15","author":"Gujrati","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ymthe.2025.07.037_bib44","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20051154","article-title":"Assessment of miR-98-5p, miR-152-3p, miR-326 and miR-4289 Expression as Biomarker for Prostate Cancer Diagnosis","volume":"20","author":"Moya","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2025.07.037_bib45","doi-asserted-by":"crossref","first-page":"6653","DOI":"10.1038\/s41598-018-24424-w","article-title":"A Plasma Biomarker Panel of Four MicroRNAs for the Diagnosis of Prostate Cancer","volume":"8","author":"Matin","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2025.07.037_bib46","doi-asserted-by":"crossref","first-page":"5700","DOI":"10.1038\/s41388-019-0823-5","article-title":"Androgen receptor-modulatory microRNAs provide insight into therapy resistance and therapeutic targets in advanced prostate cancer","volume":"38","author":"Fletcher","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.ymthe.2025.07.037_bib47","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/s12672-024-01376-4","article-title":"Recent progress in microRNA research for prostate cancer","volume":"15","author":"Yuan","year":"2024","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.ymthe.2025.07.037_bib48","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ajur.2020.06.003","article-title":"Coordinated AR and microRNA regulation in prostate cancer","volume":"7","author":"Eringyte","year":"2020","journal-title":"Asian J. Urol."},{"key":"10.1016\/j.ymthe.2025.07.037_bib49","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41419-020-02932-w","article-title":"The miR-361-3p increases enzalutamide (Enz) sensitivity via targeting the ARv7 and MKNK2 to better suppress the Enz-resistant prostate cancer","volume":"11","author":"Liu","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ymthe.2025.07.037_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108585","article-title":"Post-transcriptional Gene Regulation by MicroRNA-194 Promotes Neuroendocrine Transdifferentiation in Prostate Cancer","volume":"34","author":"Fernandes","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.ymthe.2025.07.037_bib51","doi-asserted-by":"crossref","first-page":"3356","DOI":"10.1158\/0008-5472.CAN-08-4112","article-title":"The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines","volume":"69","author":"Sun","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2025.07.037_bib52","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1002\/pros.22456","article-title":"The altered expression of MiR-221\/-222 and MiR-23b\/-27b is associated with the development of human castration resistant prostate cancer","volume":"72","author":"Sun","year":"2012","journal-title":"Prostate"},{"key":"10.1016\/j.ymthe.2025.07.037_bib53","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.gene.2015.07.017","article-title":"Effects of microRNA-221\/222 on cell proliferation and apoptosis in prostate cancer cells","volume":"572","author":"Wang","year":"2015","journal-title":"Gene"},{"key":"10.1016\/j.ymthe.2025.07.037_bib54","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0184166","article-title":"Androgen receptor-mediated downregulation of microRNA-221 and -222 in castration-resistant prostate cancer","volume":"12","author":"Gui","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2025.07.037_bib55","doi-asserted-by":"crossref","first-page":"19983","DOI":"10.1073\/pnas.0706641104","article-title":"An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells","volume":"104","author":"Shi","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.07.037_bib56","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1089\/biores.2012.9903","article-title":"miR-125b Regulation of Androgen Receptor Signaling Via Modulation of the Receptor Complex Co-Repressor NCOR2","volume":"1","author":"Yang","year":"2012","journal-title":"Biores. Open Access"},{"key":"10.1016\/j.ymthe.2025.07.037_bib57","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.3390\/jcm4101853","article-title":"MicroRNA Library-Based Functional Screening Identified Androgen-Sensitive miR-216a as a Player in Bicalutamide Resistance in Prostate Cancer","volume":"4","author":"Miyazaki","year":"2015","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ymthe.2025.07.037_bib58","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.7150\/jca.92379","article-title":"MiR-15b-3p weakens bicalutamide sensitivity in prostate cancer via targeting KLF2 to suppress ferroptosis","volume":"15","author":"Zhang","year":"2024","journal-title":"J. Cancer"},{"key":"10.1016\/j.ymthe.2025.07.037_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110099","article-title":"The dual role of mir-146a in metastasis and disease progression","volume":"126","author":"Shahriar","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ymthe.2025.07.037_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1476-4598-13-1","article-title":"MicroRNA expressions associated with progression of prostate cancer cells to antiandrogen therapy resistance","volume":"13","author":"Ottman","year":"2014","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ymthe.2025.07.037_bib61","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1261\/rna.874808","article-title":"Loss of mir-146a function in hormone-refractory prostate cancer","volume":"14","author":"Lin","year":"2008","journal-title":"RNA"},{"key":"10.1016\/j.ymthe.2025.07.037_bib62","doi-asserted-by":"crossref","first-page":"72593","DOI":"10.18632\/oncotarget.12241","article-title":"Identification of miR-30b-3p and miR-30d-5p as direct regulators of androgen receptor signaling in prostate cancer by complementary functional microRNA library screening","volume":"7","author":"Kumar","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ymthe.2025.07.037_bib63","doi-asserted-by":"crossref","first-page":"14055","DOI":"10.1002\/jcb.28680","article-title":"miR-103a-2-5p\/miR-30c-1-3p inhibits the progression of prostate cancer resistance to androgen ablation therapy via targeting androgen receptor variant 7","volume":"120","author":"Chen","year":"2019","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.ymthe.2025.07.037_bib64","doi-asserted-by":"crossref","first-page":"4130","DOI":"10.1038\/onc.2012.425","article-title":"Tumor suppressive miR-124 targets androgen receptor and inhibits proliferation of prostate cancer cells","volume":"32","author":"Shi","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.ymthe.2025.07.037_bib65","doi-asserted-by":"crossref","first-page":"5309","DOI":"10.1158\/0008-5472.CAN-14-0795","article-title":"miR-124 and Androgen Receptor Signaling Inhibitors Repress Prostate Cancer Growth by Downregulating Androgen Receptor Splice Variants, EZH2, and Src","volume":"75","author":"Shi","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2025.07.037_bib66","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3233\/TUB-211568","article-title":"MicroRNA-99b-5p targets mTOR\/AR axis, induces autophagy and inhibits prostate cancer cell proliferation","volume":"44","author":"Niture","year":"2022","journal-title":"Tumour Biol."},{"key":"10.1016\/j.ymthe.2025.07.037_bib67","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1158\/0008-5472.CAN-18-2993","article-title":"MiR-644a Disrupts Oncogenic Transformation and Warburg Effect by Direct Modulation of Multiple Genes of Tumor-Promoting Pathways","volume":"79","author":"Ebron","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2025.07.037_bib68","doi-asserted-by":"crossref","first-page":"5287","DOI":"10.1158\/1078-0432.CCR-10-2619","article-title":"Regulatory Role of mir-203 in Prostate Cancer Progression and Metastasis","volume":"17","author":"Saini","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2025.07.037_bib69","doi-asserted-by":"crossref","first-page":"25726","DOI":"10.18632\/oncotarget.8366","article-title":"Androgen receptor regulates SRC expression through microRNA-203","volume":"7","author":"Siu","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ymthe.2025.07.037_bib70","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13046-015-0125-x","article-title":"MiR-203 down-regulates Rap1A and suppresses cell proliferation, adhesion and invasion in prostate cancer","volume":"34","author":"Xiang","year":"2015","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2025.07.037_bib71","doi-asserted-by":"crossref","first-page":"51284","DOI":"10.18632\/oncotarget.9992","article-title":"Androgen-induced miR-135a acts as a tumor suppressor through downregulating RBAK and MMP11, and mediates resistance to androgen deprivation therapy","volume":"7","author":"Wan","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ymthe.2025.07.037_bib72","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12951-024-02438-z","article-title":"MiR26a reverses enzalutamide resistance in a bone-tumor targeted system with an enhanced effect on bone metastatic CRPC","volume":"22","author":"Wang","year":"2024","journal-title":"J. Nanobiotechnology"},{"key":"10.1016\/j.ymthe.2025.07.037_bib73","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0052106","article-title":"The microRNA -23b\/-27b cluster suppresses the metastatic phenotype of castration-resistant prostate cancer cells","volume":"7","author":"Ishteiwy","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2025.07.037_bib74","doi-asserted-by":"crossref","first-page":"4752","DOI":"10.1038\/onc.2016.6","article-title":"The microRNA-23b\/-27b cluster suppresses prostate cancer metastasis via Huntingtin-interacting protein 1-related","volume":"35","author":"Rice","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.ymthe.2025.07.037_bib75","doi-asserted-by":"crossref","DOI":"10.1177\/1010428318803011","article-title":"MicroRNA-23b and microRNA-27b plus flutamide treatment enhances apoptosis rate and decreases CCNG1 expression in a castration-resistant prostate cancer cell line","volume":"40","author":"Pimenta","year":"2018","journal-title":"Tumour Biol."},{"key":"10.1016\/j.ymthe.2025.07.037_bib76","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11418","article-title":"Dysregulation of miRNAs-COUP-TFII-FOXM1-CENPF axis contributes to the metastasis of prostate cancer","volume":"7","author":"Lin","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.07.037_bib77","first-page":"3226","article-title":"Epigenetic silencing of miR-137 induces resistance to bicalutamide by targeting TRIM24 in prostate cancer cells","volume":"11","author":"Guan","year":"2019","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.ymthe.2025.07.037_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2022.100875","article-title":"A trio of tumor suppressor miRNA downregulates CREB5 dependent transcription to modulate neoadjuvant hormonal therapy sensitivity","volume":"36","author":"Wang","year":"2023","journal-title":"Neoplasia"},{"key":"10.1016\/j.ymthe.2025.07.037_bib79","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1530\/ERC-20-0405","article-title":"Leptin antagonism inhibits prostate cancer xenograft growth and progression","volume":"28","author":"Philp","year":"2021","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.ymthe.2025.07.037_bib80","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-13279-x","article-title":"Leptin modulated microRNA-628-5p targets Jagged-1 and inhibits prostate cancer hallmarks","volume":"12","author":"Rios-Colon","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2025.07.037_bib81","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41580-022-00566-8","article-title":"Long non-coding RNAs: definitions, functions, challenges and recommendations","volume":"24","author":"Mattick","year":"2023","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ymthe.2025.07.037_bib82","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/s12672-024-01077-y","article-title":"Exploring the enigma: history, present, and future of long non-coding RNAs in cancer","volume":"15","author":"Naseer","year":"2024","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.ymthe.2025.07.037_bib83","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41525-024-00401-3","article-title":"Single cell-transcriptomic analysis informs the lncRNA landscape in metastatic castration resistant prostate cancer","volume":"9","author":"Saha","year":"2024","journal-title":"NPJ Genom. Med."},{"key":"10.1016\/j.ymthe.2025.07.037_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216247","article-title":"Non-coding RNAs in enzalutamide resistance of castration-resistant prostate cancer","volume":"566","author":"Gao","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ymthe.2025.07.037_bib85","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1481777","article-title":"Long noncoding RNA mediates enzalutamide resistance and transformation in neuroendocrine prostate cancer","volume":"14","author":"Zhu","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ymthe.2025.07.037_bib86","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.celrep.2015.08.069","article-title":"LncRNA HOTAIR Enhances the Androgen-Receptor-Mediated Transcriptional Program and Drives Castration-Resistant Prostate Cancer","volume":"13","author":"Zhang","year":"2015","journal-title":"Cell Rep."},{"key":"10.1016\/j.ymthe.2025.07.037_bib87","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0070372","article-title":"Genistein inhibits prostate cancer cell growth by targeting miR-34a and oncogenic HOTAIR","volume":"8","author":"Chiyomaru","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2025.07.037_bib88","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41419-020-02856-5","article-title":"LINC00675 activates androgen receptor axis signaling pathway to promote castration-resistant prostate cancer progression","volume":"11","author":"Yao","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ymthe.2025.07.037_bib89","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/s41419-021-04144-2","article-title":"LncRNA PCBP1-AS1-mediated AR\/AR-V7 deubiquitination enhances prostate cancer enzalutamide resistance","volume":"12","author":"Zhang","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ymthe.2025.07.037_bib90","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1158\/0008-5472.CAN-20-3845","article-title":"Loss of Long Noncoding RNA NXTAR in Prostate Cancer Augments Androgen Receptor Expression and Enzalutamide Resistance","volume":"82","author":"Ghildiyal","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2025.07.037_bib91","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11020216","article-title":"New Insights into Long Non-Coding RNA MALAT1 in Cancer and Metastasis","volume":"11","author":"Sun","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ymthe.2025.07.037_bib92","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1016\/j.juro.2013.07.001","article-title":"Long noncoding RNA MALAT-1 is a new potential therapeutic target for castration resistant prostate cancer","volume":"190","author":"Ren","year":"2013","journal-title":"J. Urol."},{"key":"10.1016\/j.ymthe.2025.07.037_bib93","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.eururo.2017.04.005","article-title":"Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9 (R) to Suppress Enzalutamide-resistant Prostate Cancer Progression","volume":"72","author":"Wang","year":"2017","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ymthe.2025.07.037_bib94","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.molcel.2010.08.011","article-title":"The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation","volume":"39","author":"Tripathi","year":"2010","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ymthe.2025.07.037_bib95","doi-asserted-by":"crossref","first-page":"12216","DOI":"10.1073\/pnas.97.22.12216","article-title":"PCGEM1, a prostate-specific gene, is overexpressed in prostate cancer","volume":"97","author":"Srikantan","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.07.037_bib96","doi-asserted-by":"crossref","first-page":"15481","DOI":"10.18632\/oncotarget.7139","article-title":"Regulation of androgen receptor splice variant AR3 by PCGEM1","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ymthe.2025.07.037_bib97","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1002\/1878-0261.12471","article-title":"The long noncoding RNA HORAS5 mediates castration-resistant prostate cancer survival by activating the androgen receptor transcriptional program","volume":"13","author":"Parolia","year":"2019","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.ymthe.2025.07.037_bib98","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s12943-019-1037-8","article-title":"A novel AR translational regulator lncRNA LBCS inhibits castration resistance of prostate cancer","volume":"18","author":"Gu","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ymthe.2025.07.037_bib99","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1158\/1541-7786.MCR-18-0087","article-title":"Novel lncRNA LINC00844 Regulates Prostate Cancer Cell Migration and Invasion through AR Signaling","volume":"16","author":"Lingadahalli","year":"2018","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.ymthe.2025.07.037_bib100","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1038\/emboj.2013.99","article-title":"Androgen-responsive long noncoding RNA CTBP1-AS promotes prostate cancer","volume":"32","author":"Takayama","year":"2013","journal-title":"EMBO J."},{"key":"10.1016\/j.ymthe.2025.07.037_bib101","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1531","article-title":"Androgen-repressed lncRNA LINC01126 drives castration-resistant prostate cancer by regulating the switch between O-GlcNAcylation and phosphorylation of androgen receptor","volume":"14","author":"Cai","year":"2024","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.ymthe.2025.07.037_bib102","article-title":"The Role of lncRNAs in Gene Expression Regulation through mRNA Stabilization","volume":"7","author":"Sebastian-delaCruz","year":"2021","journal-title":"Noncoding. RNA"},{"key":"10.1016\/j.ymthe.2025.07.037_bib103","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41580-020-00315-9","article-title":"Gene regulation by long non-coding RNAs and its biological functions","volume":"22","author":"Statello","year":"2021","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ymthe.2025.07.037_bib104","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/978-1-4939-3378-5_21","article-title":"Analyzing MiRNA-LncRNA Interactions","volume":"1402","author":"Paraskevopoulou","year":"2016","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ymthe.2025.07.037_bib105","doi-asserted-by":"crossref","first-page":"643","DOI":"10.21037\/tau-22-99","article-title":"Enzalutamide-resistant related lncRNA NONHSAT210528 promotes the proliferation and invasion of prostate cancer","volume":"11","author":"Ye","year":"2022","journal-title":"Transl. Androl. Urol."},{"key":"10.1016\/j.ymthe.2025.07.037_bib106","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.bulcan.2020.11.022","article-title":"The lncRNA PTTG3P promotes the progression of CRPC via upregulating PTTG1","volume":"108","author":"Huang","year":"2021","journal-title":"Bull. Cancer"},{"key":"10.1016\/j.ymthe.2025.07.037_bib107","article-title":"Enzalutamide-Induced Upregulation of PCAT6 Promotes Prostate Cancer Neuroendocrine Differentiation by Regulating miR-326\/HNRNPA2B1 Axis","volume":"11","author":"Liu","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ymthe.2025.07.037_bib108","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.2174\/1381612827666210612052317","article-title":"Long Non-coding RNA AFAP1-AS1 Facilitates Prostate Cancer Progression by Regulating miR-15b\/IGF1R Axis","volume":"27","author":"Liu","year":"2021","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ymthe.2025.07.037_bib109","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.129635","article-title":"Glycolysis related lncRNA SNHG3\/miR-139-5p\/PKM2 axis promotes castration-resistant prostate cancer (CRPC) development and enzalutamide resistance","volume":"260","author":"Yao","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ymthe.2025.07.037_bib110","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/s13046-023-02774-2","article-title":"LncRNA SNHG4 promotes prostate cancer cell survival and resistance to enzalutamide through a let-7a\/RREB1 positive feedback loop and a ceRNA network","volume":"42","author":"Dong","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2025.07.037_bib111","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.7150\/ijbs.63488","article-title":"Emerging Roles of LncRNAs in the EZH2-regulated Oncogenic Network","volume":"17","author":"Hao","year":"2021","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.ymthe.2025.07.037_bib112","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.stem.2010.08.002","article-title":"Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer","volume":"7","author":"Sauvageau","year":"2010","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ymthe.2025.07.037_bib113","doi-asserted-by":"crossref","first-page":"7349","DOI":"10.1038\/s41467-021-26901-9","article-title":"The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer","volume":"12","author":"Singh","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.07.037_bib114","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1038\/s41467-019-09784-9","article-title":"LncRNA-p21 alters the antiandrogen enzalutamide-induced prostate cancer neuroendocrine differentiation via modulating the EZH2\/STAT3 signaling","volume":"10","author":"Luo","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.07.037_bib115","doi-asserted-by":"crossref","first-page":"5383","DOI":"10.1038\/ncomms6383","article-title":"The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer","volume":"5","author":"Chakravarty","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.07.037_bib116","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1016\/j.ymthe.2017.04.016","article-title":"lncRNA HOXD-AS1 Regulates Proliferation and Chemo-Resistance of Castration-Resistant Prostate Cancer via Recruiting WDR5","volume":"25","author":"Gu","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.07.037_bib117","doi-asserted-by":"crossref","first-page":"37868","DOI":"10.18632\/oncotarget.9350","article-title":"Long noncoding RNA DANCR promotes invasion of prostate cancer through epigenetically silencing expression of TIMP2\/3","volume":"7","author":"Jia","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ymthe.2025.07.037_bib118","doi-asserted-by":"crossref","DOI":"10.3892\/ijo.2023.5482","article-title":"VIM-AS1 promotes proliferation and drives enzalutamide resistance in prostate cancer via IGF2BP2-mediated HMGCS1 mRNA stabilization","volume":"62","author":"Shi","year":"2023","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ymthe.2025.07.037_bib119","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.18632\/aging.101664","article-title":"BCAR4 activates GLI2 signaling in prostate cancer to contribute to castration resistance","volume":"10","author":"Cai","year":"2018","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.ymthe.2025.07.037_bib120","article-title":"Functions of Circular RNA in Human Diseases and Illnesses","volume":"9","author":"Gu","year":"2023","journal-title":"Noncoding. RNA"},{"key":"10.1016\/j.ymthe.2025.07.037_bib121","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104612","article-title":"Circular RNAs as Key Regulators in Cancer Hallmarks: New Progress and Therapeutic Opportunities","volume":"207","author":"Hussen","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ymthe.2025.07.037_bib122","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-47189-2","article-title":"Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide","volume":"9","author":"Greene","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2025.07.037_bib123","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41419-018-1048-1","article-title":"Preclinical study using circular RNA 17 and micro RNA 181c-5p to suppress the enzalutamide-resistant prostate cancer progression","volume":"10","author":"Wu","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ymthe.2025.07.037_bib124","article-title":"Comprehensive Characterization of Androgen-Responsive circRNAs in Prostate Cancer","volume":"11","author":"Kong","year":"2021","journal-title":"Life (Basel)"},{"key":"10.1016\/j.ymthe.2025.07.037_bib125","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1038\/s41418-021-00743-w","article-title":"Targeting androgen receptor (AR) with antiandrogen Enzalutamide increases prostate cancer cell invasion yet decreases bladder cancer cell invasion via differentially altering the AR\/circRNA-ARC1\/miR-125b-2-3p or miR-4736\/PPARgamma\/MMP-9 signals","volume":"28","author":"Deng","year":"2021","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.ymthe.2025.07.037_bib126","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2024.148818","article-title":"Circular RNA hsa_circ_0001610 promotes prostate cancer progression by sponging miR-1324 and upregulating PTK6","volume":"930","author":"Li","year":"2024","journal-title":"Gene"},{"key":"10.1016\/j.ymthe.2025.07.037_bib127","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.7150\/jca.86940","article-title":"circROBO1 promotes prostate cancer growth and enzalutamide resistance via accelerating glycolysis","volume":"14","author":"Zhou","year":"2023","journal-title":"J. Cancer"},{"key":"10.1016\/j.ymthe.2025.07.037_bib128","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.7150\/ijbs.77133","article-title":"M6A-modified circRBM33 promotes prostate cancer progression via PDHA1-mediated mitochondrial respiration regulation and presents a potential target for ARSI therapy","volume":"19","author":"Zhong","year":"2023","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.ymthe.2025.07.037_bib129","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1515\/med-2019-0097","article-title":"CircRNA-UCK2 Increased TET1 Inhibits Proliferation and Invasion of Prostate Cancer Cells Via Sponge MiRNA-767-5p","volume":"14","author":"Xiang","year":"2019","journal-title":"Open Med."},{"key":"10.1016\/j.ymthe.2025.07.037_bib130","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13246383","article-title":"hsa_circ_0001275 Is One of a Number of circRNAs Dysregulated in Enzalutamide Resistant Prostate Cancer and Confers Enzalutamide Resistance In Vitro","volume":"13","author":"Lim","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ymthe.2025.07.037_bib131","doi-asserted-by":"crossref","first-page":"7675","DOI":"10.1038\/s41467-024-52032-y","article-title":"Androgen receptor monomers and dimers regulate opposing biological processes in prostate cancer cells","volume":"15","author":"Safi","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.07.037_bib132","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41419-020-03321-z","article-title":"Suppressing BCL-XL increased the high dose androgens therapeutic effect to better induce the Enzalutamide-resistant prostate cancer autophagic cell death","volume":"12","author":"Xiang","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ymthe.2025.07.037_bib133","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41420-022-00898-6","article-title":"High-dose-androgen-induced autophagic cell death to suppress the Enzalutamide-resistant prostate cancer growth via altering the circRNA-BCL2\/miRNA-198\/AMBRA1 signaling","volume":"8","author":"Chen","year":"2022","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.ymthe.2025.07.037_bib134","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.7150\/ijbs.96173","article-title":"PiRNA-4447944 promotes castration-resistant growth and metastasis of prostate cancer by inhibiting NEFH expression through forming the piRNA-4447944-PIWIL2-NEFH complex","volume":"20","author":"Peng","year":"2024","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.ymthe.2025.07.037_bib135","doi-asserted-by":"crossref","first-page":"4795","DOI":"10.1245\/s10434-024-15453-z","article-title":"Role of MicroRNA-21 in Prostate Cancer Progression and Metastasis: Molecular Mechanisms to Therapeutic Targets","volume":"31","author":"Singh","year":"2024","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.ymthe.2025.07.037_bib136","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1002\/pros.23187","article-title":"Association of microRNA-21 expression with clinicopathological characteristics and the risk of progression in advanced prostate cancer patients receiving androgen deprivation therapy","volume":"76","author":"Guan","year":"2016","journal-title":"Prostate"},{"key":"10.1016\/j.ymthe.2025.07.037_bib137","doi-asserted-by":"crossref","first-page":"266","DOI":"10.5455\/aim.2021.29.266-269","article-title":"miRNA-21 Serum Evaluation in BPH, Hormone Sensitive Prostate Cancer, and Castrate Resistant Prostate Cancer: Attempt for Diagnostic Biomarker Evaluation","volume":"29","author":"Seputra","year":"2021","journal-title":"Acta Inform. Med."},{"key":"10.1016\/j.ymthe.2025.07.037_bib138","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1093\/clinchem\/hvaa095","article-title":"Prognostic Value of Novel Liquid Biomarkers in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide: A Prospective Observational Study","volume":"66","author":"Benoist","year":"2020","journal-title":"Clin. Chem."},{"key":"10.1016\/j.ymthe.2025.07.037_bib139","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.3389\/fonc.2019.01263","article-title":"A New Era of Prostate Cancer Precision Medicine","volume":"9","author":"Malik","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ymthe.2025.07.037_bib140","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1373\/clinchem.2012.198739","article-title":"The long and winding road to FDA approval of a novel prostate cancer test: our story","volume":"59","author":"Rittenhouse","year":"2013","journal-title":"Clin. Chem."},{"key":"10.1016\/j.ymthe.2025.07.037_bib141","first-page":"3075","article-title":"The Role of PCA 3 as a Prognostic Factor in Patients with Castration-resistant Prostate Cancer (CRPC) Treated with Docetaxel","volume":"35","author":"Bourdoumis","year":"2015","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ymthe.2025.07.037_bib142","doi-asserted-by":"crossref","first-page":"555","DOI":"10.56434\/j.arch.esp.urol.20237608.69","article-title":"The Value of Combined Detection of Serum PSA, MALAT1 and TMPRSS2-ETV1 in Evaluating the Progress and Prognosis of Prostate Cancer","volume":"76","author":"Zhao","year":"2023","journal-title":"Arch. Esp. Urol."},{"key":"10.1016\/j.ymthe.2025.07.037_bib143","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1158\/1541-7786.MCR-14-0257","article-title":"The lncRNA PCAT29 inhibits oncogenic phenotypes in prostate cancer","volume":"12","author":"Malik","year":"2014","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.ymthe.2025.07.037_bib144","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1158\/1541-7786.MCR-15-0016-T","article-title":"The lncRNA DRAIC\/PCAT29 Locus Constitutes a Tumor-Suppressive Nexus","volume":"13","author":"Sakurai","year":"2015","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.ymthe.2025.07.037_bib145","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1080\/14737159.2021.1996227","article-title":"Long non-coding RNAs and their potential impact on diagnosis, prognosis, and therapy in prostate cancer: racial, ethnic, and geographical considerations","volume":"21","author":"Morgan","year":"2021","journal-title":"Expert Rev. Mol. Diagn."},{"key":"10.1016\/j.ymthe.2025.07.037_bib146","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s41576-024-00693-2","article-title":"Targeting and engineering long non-coding RNAs for cancer therapy","volume":"25","author":"Coan","year":"2024","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.ymthe.2025.07.037_bib147","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2024.155746","article-title":"siRNA-based knockdown of lncRNAs: A new modality to target tumor progression","volume":"266","author":"Khaleel","year":"2025","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.ymthe.2025.07.037_bib148","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.eururo.2017.04.005","article-title":"Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9((R)) to Suppress Enzalutamide-resistant Prostate Cancer Progression","volume":"72","author":"Wang","year":"2017","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ymthe.2025.07.037_bib149","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1158\/2767-9764.CRC-23-0089","article-title":"Targeting MALAT1 Augments Sensitivity to PARP Inhibition by Impairing Homologous Recombination in Prostate Cancer","volume":"3","author":"Yadav","year":"2023","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.ymthe.2025.07.037_bib150","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13045-022-01230-6","article-title":"Designing strategies of small-molecule compounds for modulating non-coding RNAs in cancer therapy","volume":"15","author":"Zhao","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ymthe.2025.07.037_bib151","doi-asserted-by":"crossref","first-page":"13242","DOI":"10.1002\/anie.201808823","article-title":"Discovery of Small Molecule Ligands for MALAT1 by Tuning an RNA-Binding Scaffold","volume":"57","author":"Donlic","year":"2018","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.ymthe.2025.07.037_bib152","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.ncrna.2024.03.012","article-title":"Advanced approaches of the use of circRNAs as a replacement for cancer therapy","volume":"9","author":"Hama Faraj","year":"2024","journal-title":"Noncoding. RNA Res."},{"key":"10.1016\/j.ymthe.2025.07.037_bib153","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.43511","article-title":"Replication Study: The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44","volume":"8","author":"Yan","year":"2019","journal-title":"Elife"},{"key":"10.1016\/j.ymthe.2025.07.037_bib154","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/s41416-020-0802-1","article-title":"Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours","volume":"122","author":"Hong","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ymthe.2025.07.037_bib155","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s10637-016-0407-y","article-title":"Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors","volume":"35","author":"Beg","year":"2017","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.ymthe.2025.07.037_bib156","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1158\/1538-7445.AM2023-2716","article-title":"Abstract 2716: Further development of microRNA-34a therapeutics to target castration-resistant prostate cancer","volume":"83","author":"Li","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2025.07.037_bib157","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/s41392-022-00975-3","article-title":"Targeting non-coding RNAs to overcome cancer therapy resistance","volume":"7","author":"Chen","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ymthe.2025.07.037_bib158","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101730","article-title":"Unlocking the potential of non-coding RNAs in cancer research and therapy","volume":"35","author":"Uppaluri","year":"2023","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.ymthe.2025.07.037_bib159","article-title":"Unveiling the challenges of short non-coding RNAs and their prospects in cancer therapy","volume":"102","author":"Dharshini","year":"2024","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.ymthe.2025.07.037_bib160","doi-asserted-by":"crossref","first-page":"D129","DOI":"10.1093\/nar\/gkae1036","article-title":"miRNATissueAtlas 2025: an update to the uniformly processed and annotated human and mouse non-coding RNA tissue atlas","volume":"53","author":"Rishik","year":"2025","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2025.07.037_bib161","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s43856-024-00613-9","article-title":"Iroquois homeobox 4 (IRX4) derived micropeptide promotes prostate cancer progression and chemoresistance through Wnt signalling dysregulation","volume":"4","author":"Fernando","year":"2024","journal-title":"Commun. Med."},{"key":"10.1016\/j.ymthe.2025.07.037_bib162","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1158\/2159-8290.CD-14-1057","article-title":"A Large-Scale Analysis of Genetic Variants within Putative miRNA Binding Sites in Prostate Cancer","volume":"5","author":"Stegeman","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ymthe.2025.07.037_bib163","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1530\/ERC-15-0013","article-title":"A genetic variant of MDM4 influences regulation by multiple microRNAs in prostate cancer","volume":"22","author":"Stegeman","year":"2015","journal-title":"Endocr. Relat. Cancer"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152500162500574X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152500162500574X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:57:32Z","timestamp":1793840252000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152500162500574X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":163,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S152500162500574X"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.07.037","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rewriting androgen-targeted therapy resistance with non-coding RNAs in prostate cancer treatment","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.07.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The American Society of Gene and Cell Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}